Date: 2018-06-12
Type of information: Private placement
Company: MeiraGTx (USA - NY)
Investors:
Amount: $75 million
Funding type: private placement
Planned used:
Others:
- • On June 12, 2018, MeiraGTx announced the closing of its initial public offering of 5,000,000 ordinary shares at a public offering price of $15.00 per share. The gross proceeds to MeiraGTx, before underwriting discounts and commissions, are $75,000,000.
- • On June 7, 2018, MeiraGTx announced the pricing of its initial public offering of 5,000,000 ordinary shares at a public offering price of $15.00 per share, for total gross proceeds of approximately $75.0 million, before underwriting discounts and commissions. In addition, the company has granted the underwriters a 30-day option to purchase up to 750,000 additional ordinary shares from the Company at the initial public offering price, less the underwriting discounts and commissions.
- All of the ordinary shares are being offered by the company. The company’s ordinary shares are expected to begin trading on the Nasdaq Global Select Market on Friday, June 8, 2018 under the ticker symbol “MGTX.” The offering is expected to close on June 12, 2018, subject to customary closing conditions.
- BofA Merrill Lynch, Barclays and Evercore ISI are acting as joint book-running managers for the offering. Chardan is acting as the lead manager for the offering.
Therapeutic area: Rare diseases - Genetic diseases
Is general: Yes
